As part of the MarketWatch 50 series, Eleanor Laise interviewed Dr. Daniel Skovronsky, the chief scientific and medical officer at Eli Lilly & Co. LLY, +0.54%. The company’s stock has soared 63% this year amid excitement for its Mounjaro treatment for Type 2 diabetes. This is a GLP-1 medication, competing with Wegovy and Ozempic, which are made by Novo Nordisk A/S NVO, +0.32%. This category of medicine leads to such dramatic weight loss that it could affect a number of other industries.
Shares of Warner Bros. Discovery Inc. WBD, +2.61% plunged 19% on Wednesday after the company warned that it will not be able to pay down debt as quickly as it had planned if the TV advertising market doesn’t recover. Another factor that may have upset investors was a 700,000 decline in direct-to-consumer subscriptions.
WBD in its current form was created on April 8, 2022, when AT&T Inc. T, -0.51% divested WarnerMedia, which was merged with Discovery Inc. Here’s a chart for the combined company’s stock price since that date:Earnings season and IPO buyers’ remorse There was a long period during which low interest rates helped support many initial public offerings, with shares often soaring on the first day of trading.
Therese Poletti: Disney CEO Bob Iger is getting his hands dirty as he focuses on studio woes — will be it enough?New tax rules and advice for tax planning Andrew Kesher explains changes in tax brackets and rules for 2024:Stock picks When you see how people suffer from hurricanes or floods, you might wonder why anyone would choose to live in the affected areas. Michael Brush explains how to profit from peoples’ location preferences over the long term.